LENZ Therapeutics, Inc. (LENZ) Misses Q2 EPS by 40c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi
August 15, 2024 4:58 AM EDTCiti analyst Yigal Nochomovitz lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $32.00 (from $34.00) while maintaining a Buy rating.
The analyst comments "LENZ continues to execute very effectively on pre-commercialization plans for LNZ100 in presbyopia. While there was not... More
